R&D Tools

Caris Life Sciences® offers unparalleled precision medicine services that are designed to maximize the chances of success for clinical trials and address many patient accrual challenges facing biopharma partners in the world of precision medicine.​

CarisDEAN: Deliberation Analytics

AI on a molecular level

Our proprietary and advanced AI platform uses the largest existing dataset of tumor profiling results, matched with clinical outcomes, to identify new cancer subtypes with specifically defined molecular signatures.

DEAN creates and validates dozens of machine learning proprietary signatures to provide the most in-depth and exclusive analysis and interpretation. DEAN learns from patient data, including what patients were treated with and their outcomes, and uses a non-linear feature selection to find relevant associations in the cast informatic space that our profiling generates.

Caris Next Generation Profiling™, which is powered by DEAN, identifies unique molecular signatures by cancer subtype to help predict which patients may respond to specific treatments, making clinical assessment more precise. This has the potential to improve cancer diagnosis and therapeutic guidance in ways never before possible.

DEAN enables MI GPS™ (Genomic Profiling Similarity) Score, a proprietary algorithm that molecularly classifies cancer into dozens of distinct molecular subtypes that refine and improve current diagnostic standards and informs more personalized and precise treatment.

CarisADAPT: Biotargeting System

Revolutionary, blood-based biotargeting technology

An innovative and versatile unbiased profiling platform that identifies novel molecular targets to inform and enhance drug development and advanced diagnostics. ADAPT measures thousands of protein aberrations and is being used to characterize protein differences in individual patient tumors, develop early cancer detection assays, and discover novel drug targets. Currently, ADAPT is being developed for cancer and other complex diseases, yet has applications spanning therapy development, drug delivery, diagnostic and disease monitoring.

CarisNGP: Next Generation Profiling

Predict which patients will best respond to specific treatments based on their individual molecular profiles

Caris Next Generation Profiling (NGP) uses the power of DEAN (Deliberation Analytics) artificial intelligence and machine learning technology to provide oncologists with the most thorough molecular analysis classification to inform decision making.

Caris GPSai technology has been demonstrated to accurately identify tumor origin using molecular information. This is especially important to provide an unequivocal result when there is ambiguity about tissue of origin. The use of Caris GPSai technology with machine learning algorithms will help to understand non-linear relationships at the molecular level to improve cancer diagnosis and treatments tailored molecular subtype.

Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type


  • CUP occurs in as many as 3–5% of patients when standard diagnostic tests are not able to determine the origin of cancer.
  • Caris GPSai (Genomic Prevalence Score) is an AI that uses genomic and transcriptomic data to elucidate tumor origin.
  • The algorithm was trained on molecular data from 57,489 cases and validated on 19,555 cases.
  • GPSai predicted the tumor type out of 21 options in the labeled data set with an accuracy of over 94% on 93% of cases.
  • When also considering the second highest prediction, the accuracy increases to 97%.

Biopharma

Caris is at the intersection of science, medicine and information​.

Clinical Trials

Connecting patients with the most up-to-date and relevant clinical trials​.

Need Support?
Contact Us
or call 1.888.979.8669 (international: +41 21 533 53 00)